Immunotherapy and Vaccination in Surgically Resectable Non-Small Cell Lung Cancer (NSCLC)

Early-stage NSCLC (stages I and II, and some IIIA diseases) accounts for approximately 30% of non-small cell lung cancer (NSCLC) cases, with surgery being its main treatment modality. The risk of disease recurrence and cancer-related death, however, remains high among NSCLC patients after complete s...

Celý popis

Podrobná bibliografie

Hlavní autoři:	Li-Chung Chiu, Shu-Min Lin, Yu-Lun Lo, Scott Chih-Hsi Kuo, Cheng-Ta Yang, Ping-Chih Hsu
Médium:	Artigo
Jazyk:	Inglês
Vydáno:	MDPI AG 2021-06-01
Edice:	Vaccines
Témata:	immunotherapy programmed death-ligand 1 (PD-L1) cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) immune checkpoint inhibitor non-small cell lung cancer (NSCLC) cancer vaccination
On-line přístup:	https://www.mdpi.com/2076-393X/9/7/689
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!